title: Is p53 and heat shock protein 70 expression a useful parameter for preoperative hyperthermoradiation therapy in advanced rectal carcinoma.
abstract: OBJECTIVE
  The purposes of preoperative hyperthermoradiation (HR) therapy in advanced rectal carcinoma is to decrease the tumor mass and local recurrence after the operation and to improve long-term survival. The aim of this study was to investigate useful parameters of preoperative HR therapy in advanced rectal carcinoma.
  
  
  METHODS
  Thirty-seven patients with primary advanced rectal carcinoma located in the lower part of the rectum were treated with preoperative HR therapy followed by a curative resection of the rectum. Immunohistochemical staining for p53 and heat shock protein (HSP) 70 was performed on biopsied specimens obtained from 24 of them.
  
  
  RESULTS
  For both p53- and HSP 70-positive tumors the effect of HR therapy was good and survival rates were better than with for other tumors, but there was no significant correlation between HSP 70 expression and the effect of HR therapy and survival rates. And there was also no significant correlation between p53 expression and the effect of HR therapy and survival rates. HR therapy had a significant effect on the G or G4 tumors compared with G1 or G2 tumors (p = 0.0277).
  
  
  CONCLUSIONS
  Immunohistochemical detection of p53 and HSP 70 expressions may be useful for hyperthermoradiosensitive patients with advanced rectal carcinoma selected for preoperative HR therapy. HR therapy had a significant effect on G3 or G4 tumors compared with G1 or G2 tumors.
authors.affiliation: Department of General Surgical Science (Surgery I), Gunma University, Graduate School of Medicine, Gunma, Japan. yukinao@dream.ocn.ne.jp
authors.forename: Kunio
authors.initials: K
authors.lastname: Takeuchi
authors.forename: Masanobu
authors.initials: M
authors.lastname: Nakajima
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Miyazaki
authors.forename: Munenori
authors.initials: M
authors.lastname: Ide
authors.forename: Takayuki
authors.initials: T
authors.lastname: Asao
authors.forename: Kiníchi
authors.initials: K
authors.lastname: Fujita
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kuwano
mesh_terms: D000328:Adult; D000368:Aged; D001706:Biopsy; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D005260:Female; D005500:Follow-Up Studies; D018840:HSP70 Heat-Shock Proteins / Q000032:analysis*; D006801:Humans; D007124:Immunoenzyme Techniques; D007223:Infant; D008297:Male; D008875:Middle Aged; D009336:Necrosis; D020360:Neoadjuvant Therapy; D012004:Rectal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D012007:Rectum / Q000473:pathology; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*
chemical_list: D018840:HSP70 Heat-Shock Proteins; D016159:Tumor Suppressor Protein p53